Trial Profile
Assessment of the Risk of Inhibitor Formation in Subjects With Severe Hemophilia A When Switched From a Replacement Therapy With a rFVIII Produced by a Chinese Hamster Ovary (CHO) Cell Line to a rFVIII Produced by a Baby Hamster Kidney (BHK) Cell Line (Kogenate FS).
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 01 Jan 2015
Price :
$35
*
At a glance
- Drugs Octocog alfa (Primary)
- Indications Haemophilia A
- Focus Adverse reactions
- Sponsors Bayer
- 09 Mar 2009 New trial record